TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure. This study is conducted in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agenc ...

Emergent BioSolutions (EBS) Conference Summary Company Overview - Emergent BioSolutions is a biopharma company with a focus on biodefense and medical countermeasures, established for over 25 years [2][3] - The company produces critical products for the U.S. Government and allied nations, including vaccines and therapeutics for smallpox, anthrax, Ebola, and botulism [3][4][22] Core Products and Market Position - Key products include: - Tymbexa (smallpox vaccine) - Sifendis (anthrax vaccine) - BioThrax (anthrax treatment) - Ibanga (Ebola treatment) - Narcan (opioid overdose reversal) [21][22][30] - Narcan is the largest product, with a market share of approximately 70-75% in the naloxone category [37] Financial Performance and Strategic Plan - Emergent aims for revenue between $750 million to $850 million and adjusted EBITDA of $150 million to $200 million for fiscal 2025 [43] - Adjusted EBITDA improved from negative in 2023 to $183 million in 2024, indicating a successful stabilization phase [14][43] - The company is currently in a turnaround phase, focusing on investments in R&D and business development to drive growth [15][41] Challenges and Opportunities - The company faced significant debt issues, which have been addressed through debt reduction and maturity extensions [9][12] - Emergent is working to enhance the accessibility of Narcan, aiming to include it in first aid kits and increase distribution through partnerships with retailers and e-commerce platforms [30][34][36] Regulatory and Market Environment - Emergent benefits from bipartisan support for biodefense initiatives, which is crucial for securing government contracts [20] - The company manufactures products in the U.S. and Canada, minimizing the impact of tariffs and aligning with reshoring trends in the pharmaceutical industry [48][50] Future Aspirations - The long-term goal is to transform Emergent into a sustainable growth company, with a focus on reducing opioid overdose deaths and expanding international market presence [57][58] - The company aims to leverage its CDMO capabilities to assist other pharmaceutical companies in bringing manufacturing back to the U.S. [51][53] Conclusion - Emergent BioSolutions is positioned to play a critical role in public health through its innovative products and strategic initiatives aimed at addressing pressing health threats, particularly in the context of opioid overdoses and biodefense [36][57]

Emergent BioSolutions (EBS) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Company Participants Frank Vargo - VP - Assistant TreasurerJoseph Papa - CEO, President & DirectorRichard Lindahl - EVP, CFO & TreasurerYi Chen - Managing Director, Equity Research Conference Call Participants Jessica Fye - Managing Director & Equity Research Analyst - Biotechnology Operator Good day, and thank you for standing by. Welcome to the First Quarter twenty twenty five Emergent BioSolutions, Inc. Earnings Conference Call. A ...

Emergent BioSolutions (EBS) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the First Quarter twenty twenty five Emergent BioSolutions, Inc. Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. Please be advised that today's conference is being recorded. I wo ...

Core Insights - Bavarian Nordic A/S has received an additional contract option from BARDA valued at USD 143.6 million for the supply of freeze-dried JYNNEOS smallpox vaccine [1][10] - The new contract options will support the manufacturing and supply of the freeze-dried formulation, which has an extended shelf life, with deliveries planned for 2026 [2][8] Financial Guidance - Bavarian Nordic's financial guidance for 2025 remains unchanged, projecting total revenues between DKK 5,700 million and DKK 6,700 million, with an EBITDA margin of 26-30% [3] - Revenue from the Public Preparedness business is expected to be between DKK 3,000 million and DKK 4,000 million, with DKK 2,650 million already secured, reflecting an increase of DKK 150 million due to the exercise of the options [3] Product Development and Approval - The freeze-dried formulation of JYNNEOS was approved by the FDA in March 2025, offering advantages in transportation, storage, and shelf life compared to the liquid-frozen version [8] - JYNNEOS is the first smallpox vaccine developed under Project BioShield, which aims to enhance the availability of medical countermeasures against various threats [6] Historical Context - Bavarian Nordic has been collaborating with the U.S. government since 2003 for the development and supply of smallpox vaccines, including the liquid-frozen formulation supplied since 2010 [5][7] - The company has a ten-year contract awarded in 2017, which includes options valued at USD 299 million for the fill and finish of freeze-dried vaccines, of which USD 284 million has been exercised to date [7]